Endothelial nitric oxide synthase enhancer for protection of endothelial function from asymmetric dimethylarginine–induced injury in human internal thoracic artery  by Xuan, Chao et al.
Xuan et al Evolving Technology/Basic ScienceEndothelial nitric oxide synthase enhancer for protection of
endothelial function from asymmetric dimethylarginine–induced
injury in human internal thoracic arteryChao Xuan, MPhil,a Feng-Jun Chang, MD,b Xiao-Cheng Liu, MD,a Xiao-Yan Bai, MD,a
Xiao-Long Liao, MD,b Guo-Wei He, MD, PhD, DSc,a,c and Jing-Song Ou, MD, PhD, FCCPbFrom T
Univ
of As
sen U
and S
Fully su
(No.
(2009
and T
& 10
China
versit
ence
Infor
Disclos
C.X. an
Receive
publi
Address
cular
Tianj
com)
Affili
5100
0022-52
Copyrig
doi:10.1
T
/B
SObjectives: Endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine is a cardiovascular risk
factor that is elevated in patients with coronary artery disease. We hypothesized that novel endothelial nitric ox-
ide synthase enhancer AVE3085 might improve the endothelial function altered by asymmetric dimethylargi-
nine in the human internal thoracic artery.
Methods:Cumulative concentration-relaxationcurves to acetylcholine (11 to5 logmol/L)were established in left
internal thoracic artery rings (n¼ 65) from 27 patients undergoing coronary artery bypass grafting in precontraction
induced by U46619 (8 log mol/L) in the absence or presence of asymmetric dimethylarginine (100 mmol/L) or
AVE3085 (30 mmol/L). Protein expressions of endothelial nitric oxide synthase and levels of superoxide anion
production were detected.
Results:Maximal relaxation inducedby acetylcholinewas significantly attenuated by asymmetric dimethylarginine
(12.7%  2.3% vs 35.3%  5.0% in control; P<.05) and significantly restored by AVE3085 (23.4%  2.8%;
P<.05). AVE3085 also markedly restored endothelial nitric oxide synthase expression (0.29  0.008; P ¼ .012)
reduced by asymmetric dimethylarginine (0.05  0.04 vs 0.36 0.03 in control; P¼ .014). Increased superoxide
anion production by asymmetric dimethylarginine (2.97 0.25 vs 0.51 0.10 relative light units/[s/mg] in control;
P<.05) was inhibited by AVE3805 (0.62  0.104 relative light units/[s/mg]; P<.05).
Conclusions: AVE3085 may restore endothelium-dependent relaxation reduced by asymmetric dimethylargi-
nine through upregulation of endothelial nitric oxide synthase expression and inhibition of production of super-
oxide anion in human internal thoracic artery. These findings provide new insights into endothelial protection of
coronary bypass grafting vessels to improve long-term patency of grafts. (J Thorac Cardiovasc Surg
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The Journal of Thoracic and CaIt acts as an endogenous inhibitor of endothelial nitric oxide
synthase (eNOS) by competing with L-arginine, and this in
turn causes endothelial dysfunction.1 Alternatively, ADMA
may uncouple eNOS, leading not only to the loss of nitric
oxide but also to increased superoxide production in the
vascular endothelium and induced apoptosis of endothelial
cells.2 Superoxide anion generation also can scavenge nitric
oxide to impair vascular function and inhibit vasodilation.3
The occurrence of cardiovascular end points in high-risk pa-
tients has been found to be directly and independently asso-
ciated with elevated ADMA concentrations in patients with
coronary artery disease,4 diabetes mellitus,5 and chronic
heart failure.6
Recently, 2 new small–molecular weight compounds
(AVE9448 and AVE3085) were developed to increase endo-
thelial nitric oxide production by simultaneous upregulation
of eNOS expression and reversal of eNOS uncoupling.7 It
has been demonstrated that impaired eNOS production is en-
hancedbyAVE3085 treatment in the hind limbof severely di-
abetic animals and that treatmentwithAVE3085 significantly
increases eNOSmessenger RNAand protein levels in cardiac
tissue.8,9 Further, we have recently demonstrated that use of
AVE3085 protects porcine coronary endothelium from
ischemia–reperfusion or hypoxia–reoxygenation injury andrdiovascular Surgery c Volume 144, Number 3 697
Abbreviations and Acronyms
ADMA ¼ asymmetric dimethylarginine
ANOVA ¼ analysis of variance
CI ¼ confidence interval
DMSO ¼ dimethyl sulfoxide
Emax ¼ maximal relaxation
EC50 ¼ 50% effective concentration
eNOS ¼ endothelial nitric oxide synthase
LITA ¼ left internal thoracic artery
RLU ¼ relative light units
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model.10,11 In addition, AVE3085 has been shown to
ameliorate endothelial dysfunction in db/db mice through
increased nitric oxide bioavailability, which reduces
oxidative stress in the vascular wall.12 This study was there-
fore designed to test the hypothesis thatADMAhas detrimen-
tal effects on the endothelial function in the human internal
thoracic artery, including both decreased nitric oxide-
mediated relaxation and increased superoxide anion produc-
tion, and that AVE3085 could restore these functions.
MATERIALS AND METHODS
Vessel Preparation
The discarded left internal thoracic artery (LITA) segments from patients
undergoing coronary artery bypass grafting (n¼ 27; Table 1) were immedi-
ately collected for transfer to the laboratory. Approval to use the discarded
human vessel tissue was given by the ethics committee (institutional review
board) of TEDA International Cardiovascular Hospital, Tianjin, China.Dur-
ing coronary artery bypass grafting with LITA grafts, the LITA was har-
vested as a full pedicle. The length required for grafting was carefully
measured, usually immediately after the dissection of the LITA pedicle.
The redundant distal end was trimmed off and immediately placed inTABLE 1. Demographic and clinical characteristics of the patients
(n ¼ 27)
Age (y, mean  SEM) 60.6  5.1
Sex (no.)
Female 11 (40.7%)
Male 16 (59.3%)
Smoking habit (no.) 13 (48.1%)
Body mass index (kg/m2, mean  SEM) 26.11  3.40
Blood pressure (mm Hg, mean  SEM)
Systolic 132.7  16.7
Diastolic 77.2  11.9
Diabetes mellitus (no.) 19 (70.4%)
Unstable angina (no.) 22 (81.5%)
Total cholesterol (mmol/L, mean  SEM) 4.72  1.03
Triglycerides (mmol/L, mean  SEM) 1.74  0.95
HDL cholesterol (mmol/L, mean  SEM) 1.08  0.25
LDL cholesterol (mmol/L, mean  SEM) 3.0 5  0.86
Nitroglycerin* (no.) 27 (100%)
Dopamine* (no.) 1 (3.7%)
HDL,High-density lipoprotein; LDL, low-density lipoprotein. *Use of vasodilators or
vasoconstrictors during the harvesting of the left internal thoracic artery.
698 The Journal of Thoracic and Cardiovascular Surga container with oxygenated physiologic salt solution, maintained at 4C,
and transferred to the laboratory within 5 to 10 minutes. The adherent
connective tissue was carefully dissected, and the LITA was cut precisely
into 3-mm long segments. Organ baths in the myograph were filled with
Krebs solution, maintained at 37C and aerated continuously with a mixture
of 95% oxygen and 5% carbon dioxide. The modified Krebs solution had
the following composition: sodium ion, 144 mmol/L; potassium ion,
5.9 mmol/L; calcium ion, 2.5 mmol/L; magnesium ion, 1.2 mmol/L; chlo-
ride ion, 128.7mmol/L; hydrogen carbonate ion, 25mmol/L; sulfate ion, 1.2
mmol/L; dihydrogen phosphate ion, 1.2 mmol/L; and glucose, 11 mmol/L.
Myograph Techniques
Human LITA ring segments were suspended on wire hooks in a 6-mL
bath on a myograph modified for large vessel studies (model 610M;
DMT Company, Aarhus, Denmark). Each ring segment resting unstretched
on thewire hooks was equilibrated in Krebs solution for at least 60minutes.
Normalization
A technique described previously in detail elsewhere was used in this
study.13Briefly, each ring segmentwas stretchedup inprogressive steps every
minute to determine the individual length–tension curve. A computer itera-
tive fitting program (Myodaq and Myodata version 2.01; Maastricht Univer-
sity, Maastricht, The Netherlands) was used to determine the exponential
curve pressure and the internal diameter. At the end of each step, the internal
diameter (in micrometers) and the corresponding wall tension (in millinew-
tons per square millimeter) were recorded. When the transmural pressure on
the rings reached 100mmHg, as determined according to the length–tension
curves, the stretching procedure was stopped, and the rings were released to
90% of their internal circumference at 100 mm Hg.13,14 This degree of
passive tension was then maintained throughout the experiment.
Western Blot Analysis of eNOS
LITA samples were homogenized in lysis buffer (KeyGEN, Inc, Nanj-
ing, China), and the lysates were incubated in ice for 1 hour followed by
10 minutes of centrifugation at 10,000 rpm. After the sample was heated
at 100C for 5 minutes to denature it, 120 mg protein for each sample
was separated by 8% polyacrylamide gel electrophoresis (Page Gel, Inc,
San Diego, Calif) together with the prestained protein ladder (MBI Fer-
mentas, Inc, Glen Burnie, Md). The proteins were transferred electropho-
retically to the polyvinylidene fluoride membrane (Millipore, Billerica,
Mass). The membrane was blocked with blocking buffer (tris-buffered sa-
line solution, 0.1% polysorbate 20, 5% nonfat dry milk) for 3 hours at
room temperature and incubated with primary antibody against eNOS
(1:1,000; Cell Signaling Technology, Inc, Boulder, Colo) overnight at
4C. Equivalent protein on the same lane was confirmed by stripping and
reblotting with glyceraldehyde 3-phosphate dehydrogenase (1:1000; Cell
Signaling Technology). The secondary goat antirabbit antibody conjugated
to horseradish peroxidase (Santa Cruz Biotechnology, Inc, Santa Cruz, Ca-
lif) at a dilution of 1:5000 was added the next day. Finally, blots were de-
veloped with an enhanced chemiluminescence detection system
(Amersham Pharmacia ECL reagents; GE Healthcare Biosciences, Piscat-
away, NJ) and exposed to x-ray films. The protein bands were quantified
with QuantityOne software (Bio-Rad Laboratories, Inc, Hercules, Calif),
normalized by glyceraldehyde 3-phosphate dehydrogenase, and expressed
as multiples of control.
Superoxide Anion Measurement in Human Thoracic
Artery
LITAvessels were gently cut open longitudinally to expose the endothe-
lial surface and incubated in oxygenated Krebs buffer with drugs at 37C
for 2 hours before measurement. The segments were then rinsed briefly
in Krebs– 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid and main-
tained at 37C for 30 minutes. Lucigenin-enhanced chemiluminescenceery c September 2012
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L). Time-based reading of the fluorescence microplate reader was recorded
by softMax pro v5.0.1 software. The luminescence in relative light units
(RLU) per second for each samplewas averaged between 5 and 10minutes.
Values of blank chambers that contained the same reagents were recorded
as background, and the background values were subtracted from those of
the corresponding vessel samples. Data were normalized to vessel dry
weight and were represented as RLU per second per milligram dry weight.
Experimental Protocol
Ring segments were precontracted with U46619 at a concentration of
108 mol/L. Our previous studies showed that U46619 at 108 mol/L in-
duced 60% to 80% of maximal contractile responses in the LITA ring
segments.13,14
Effects of ADMA and AVE3085 on Acetylcholine-
Induced Endothelium-Dependent Relaxation
The LITA ring segments from the same patient were allocated randomly
into 3 groups (n ¼ 8 per group). In 1 group, the LITA ring segments were
incubated with Krebs solution as a control. In the other 2 groups, the LITA
ring segments were incubated with Krebs solution in the presence of
ADMA (100 mmo/L) or ADMA (100 mmol/L) with AVE3085 (30 mmol/L,
dissolved in dimethyl sulfoxide [DMSO]) for 1 hour before the precontrac-
tion was started.
The acetylcholine-induced relaxation in the presence of DMSO (the sol-
vent of AVE3085) was also tested to exclude the effect of the solvent (n¼ 8
in each group). In 1 group, the LITA segment was incubated with Krebs so-
lution in the presence of ADMA (100 mmol/L), and in the other group, the
LITA segments were incubated with Krebs solution in the presence of
ADMA (100 mmol/L) plus DMSO for 1 hour before the precontraction
was started. The results were then compared with those of the Krebs solu-
tion control.
In separate rings (n¼ 4), the endotheliumwasmechanically removed by
gently rubbing the luminal surface of the ring with small plastic tubing (en-
dothelium-denuded vessels).
Ring segments were precontracted with U46619 (108 mol/L).When the
contraction reached a stable plateau, acetylcholine (1011 to 105 mol/L)
was applied to a cumulative concentration at an interval between doses
to allow the relaxation induced by the previous dose to reach a plateau.
The relaxation was expressed as percentage reversal of the U46619-
induced precontraction.
Western Blot Analysis of eNOS
Immediately after the previously described relaxation study, the LITA
segments for control, ADMA, and ADMA with AVE3085 were flash-
frozen in liquid nitrogen and stored at80C for protein study (n ¼ 8 in
each group). The previously mentioned steps for eNOS measurement
were then repeated. The total exposure time for the vessel to study of the
protein expression was 5.56  0.25 hours.
Measurement of Superoxide Anion
The LITA ring segments from the same patient were allocated randomly
into 3 groups (n ¼ 7 in each group). After 30 minutes of equilibration of
each segment in the organ chamber, the LITA ring segments were incu-
bated with Krebs solution (control) or with Krebs solution in the presence
ofADMA (100mmol/L) orADMA (100mmol/L)withAVE3085 (30mmol/L)
for 2 hours. The previously mentioned steps for superoxide anion mea-
surement were then repeated.
Data Analysis
Relaxation was expressed as the percentage decrease in isometric force
induced by U46619. Mean maximal relaxation (Emax) for each group was
calculated from the maximal relaxation of different rings induced byThe Journal of Thoracic and Caacetylcholine. The effective concentration of acetylcholine that caused
50% of Emax was defined as EC50. The EC50 was determined from each
concentration–relaxation curve by a logistic, curve-fitting equation:
E ¼ MAP/(AP þ KP), where E is response, M is maximal relaxation
(Emax), A is concentration, K is EC50, and P is the slope parameter. From
this fitted equation, the mean EC50  SEM was calculated for each group.
All statistical analyses were performed with the SPSS statistical soft-
ware package (version 10.0; International Business Machines Corp, Ar-
monk, NY). All values are expressed as mean  SEM. Statistical
comparisons of the percentage relaxation under different treatments were
performed by 2-way analysis of variance (ANOVA; general linear model)
with repeated measures, followed by post hoc Bonferroni test to detect the
individual differences. The comparison of the Emax was performedwith un-
paired t test. EC50, eNOS expression, and superoxide anion were compared
by 1-way ANOVA followed by post hoc Bonferroni test. The 95% confi-
dence interval (CI) for difference was also shown when possible; n values
refer to number of ring segments from separate patients.
Drugs
Acetylcholine and ADMA were purchased from Sigma-Aldrich (St
Louis, Mo). U46619 was from Cayman Chemical (Ann Arbor, Mich).
AVE3085 was kindly provided by Sanofi-Aventis Deutschland GmbH
(Frankfurt, Germany) and dissolved in DMSO. Others were dissolved in
distilled water. Stock solutions of U46619 and acetylcholine were kept at
20C until required.RESULTS
Among the groups of the patients whose LITAs were
studied, there were no differences with regard to the clinical
characteristics (P > .05 among the groups, details not
shown; Table 1).Resting Parameters
The internal diameter of the vessels at an equivalent
transmural pressure of 100 mm Hg was 1.82  0.07 mm
(n ¼ 44), as determined from the computerized normaliza-
tion procedure. The resting transmural pressure was 81.8 
1.0 mm Hg at 90% of this value. The resting force of the
LITA rings was 2.3  0.09 g.Effect of ADMA and AVE3085 on Acetylcholine-
Induced Relaxation
The acetylcholine-mediated relaxation was abolished in
the endothelium-denuded rings (Figure 1, A). This result
shows that the acetylcholine-induced relaxation in our ex-
periments was endothelium dependent (Figure 1, B).
The acetylcholine-mediated relaxationwas significantly in-
hibited in the presence of ADMA (P< 0.001 by 2-way
ANOVA). In comparison with ADMA alone, addition of
AVE3085 toADMAsignificantly increased the acetylcholine-
induced relaxation (P¼ .001 by 2-wayANOVA; Figure 1,B).
Further, the Emax induced by acetylcholine (35.3% 
5.0% in control; 95% CI 25.1%–45.5%) was significantly
reduced in the rings treated with ADMA (12.7%  2.3%;
95% CI 8.0%–17.3%; P < .05 by unpaired t test) or
ADMA with AVE3085 (23.4%  2.8%; 95% CI 17.6%–
29.1%;P<.05 by unpaired t test). In addition, in comparisonrdiovascular Surgery c Volume 144, Number 3 699
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FIGURE 1. A,Mean concentration (logM)–relaxation (percentage rever-
sal of U46619-induced contraction) curves for acetylcholine (ACh) of left
internal thoracic artery rings with endothelium (Eþ, n¼ 8) or without endo-
thelium (E, n ¼ 4). B, Mean concentration–relaxation curves for acetyl-
choline (ACh) of left internal thoracic artery rings (n ¼ 8 in each group)
in the absence or presence of asymmetric dimethylarginine (ADMA) or
asymmetric dimethylargininewithAVE3085 (ADMAþAVE). Ringswith en-
dothelium were regarded as control. Values are expressed as mean SEM.
Asterisk indicates P<.001 versus control group; dagger indicates P<.05
versus asymmetric dimethylarginine group; 2-way analysis of variance.
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Swith ADMA alone, addition of AVE3085 to ADMA signifi-
cantly increased the Emax induced by acetylcholine (P<.05
by unpaired t-test).
With respect to the EC50, it was not significantly different
among groups (control,6.99  0.30 log mol/L; ADMA,
6.49  0.21 log mol/L; ADMA with AVE3085,7.27 
0.33 log mol/L; P>.05 by 1-way ANOVA).1 1 1 0 9 8 7 6 5
ACh [-log M]
50
FIGURE 2. Mean concentration (log M)–relaxation (percentage reversal
of U46619-induced contraction) curves for acetylcholine (ACh) in the left
internal thoracic artery rings (n ¼ 8 in each group) in the absence or pres-
ence of asymmetric dimethylarginine (ADMA) or asymmetric dimethylar-
ginine with dimethyl sulfoxide (ADMAþDMSO). Data are shown as mean
 SEM. Asterisk indicates P<.001 versus control group by 2-way analysis
of variance.Effect of DMSO on Acetylcholine-Induced
Relaxation
The acetylcholine-mediated relaxation was significantly
inhabited in the presence of ADMA and ADMA with
DMSO (P<.001 by 2-way ANOVA) but was not signifi-
cantly different between ADMA and ADMA with DMSO
(P>.05 by 2-way ANOVA; Figure 2).
In comparison with ADMA alone (14.9% 1.2%; 95%
CI 12.4%–17.4%), addition of DMSO to ADMA did not700 The Journal of Thoracic and Cardiovascular Surgalter the Emax induced by acetylcholine (14.4%  1.5%,
95% CI 11.3%–17.5%; P>.05 by unpaired t test).
The EC50 was not significantly different between the
ADMA and ADMAwith DMSO groups (ADMA,7.04 
0.30 log mol/L; ADMA with DMSO, 6.57  0.44 log
mol/L; P>.05 by 1-way ANOVA).Protein Expressions of eNOS: Effects of ADMA and
AVE3085
Expression of eNOS protein in LITA segments was sig-
nificantly decreased after incubation with ADMA (0.05 
0.04 vs 0.36 0.03 in control; P¼ .014 by 1-way ANOVA).
Addition of AVE3085 to ADMA markedly increased the
expression level of eNOS (0.29  0.008; P ¼ .012 vs
ADMA alone by 1-way ANOVA), although there was still
a difference between ADMA with AVE3085 and control
(0.29  0.008 vs 0.36  0.03 in control; P ¼ .026 by
1-way ANOVA; Figure 3).Superoxide Anion Production: Effects of ADMA and
AVE3085
As shown in Figure 4, superoxide anion generation in
LITA segments was low under basal conditions (0.51 
0.102 RLU/[s/mg]). ADMA dramatically increased super-
oxide anion production (2.97  0.25 RLU/[s/mg]; P<.05
vs control by 1-way ANOVA). Addition of AVE3085 signif-
icantly inhibited the ADMA-induced superoxide anion gen-
eration (0.62 0.104 RLU/[s/mg]; P<.05 vs ADMA group
by 1-way ANOVA).DISCUSSION
This study has demonstrated in human internal thoracic
artery samples that (1) increased ADMA levels directlyery c September 2012
FIGURE 3. Protein expression of endothelial nitric oxide synthase
(eNOS) in human left internal thoracic artery rings. Arterial rings were in-
cubated with asymmetric dimethylarginine (ADMA) in Krebs solution with
or without the addition of AVE3085 (AVE) or for the same period in Krebs
solution alone (control). Date are shown as mean  SEM. Asterisk indi-
cates P<.05 versus control group; hatch mark indicates P<.05 versus
asymmetric dimethylarginine group; n ¼ 8, 1-way analysis of variance.
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.
FIGURE 4. Superoxide production in human left internal thoracic artery
rings. Vascular rings were incubated with asymmetric dimethylarginine
(ADMA, 100 mmol/L) in Krebs solution with or without the addition of
AVE3085 (AVE, 30 mmol/L) or in Krebs solution alone (control). Data
are shown as mean SEM. Asterisk indicates P<.05 versus control group;
hatch mark indicates P<.05 versus asymmetric dimethylarginine group;
n ¼ 7; 1-way analysis of variance. RLU, Relative light units.
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expression of eNOS and by increasing superoxide anion
production and (2) these 2 mechanisms damaging the endo-
thelial function may be partially reversed by the eNOS en-
hancer AVE3085. Because endothelial function is one of the
major factors influencing the long-term patency of coronary
artery bypass grafting conduits, these findings provide new
insights in the protection of the endothelium of coronary by-
pass grafting conduits to improve the long-term patency of
these grafts.
Nitric oxide has been widely regarded as the major medi-
ator of endothelium-dependent vasodilation and plays a cru-
cial role in the endothelium-mediated regulation of vascular
homeostasis. It also regulates the vascular structure and
cell–cell interactions in blood vessels.15 A relatively newly
found and intriguing mechanism that leads to a reduction in
nitric oxide is ADMA, an endogenous competitive inhibitor
of eNOS that has been linked to endothelial dysfunction.2
Importantly, it has been demonstrated that elevated
ADMA concentrations are found in patients with coronary
artery disease and other related diseases, such as diabetes
mellitus and chronic heart failure.4-6
It has been reported that ADMA induces the production
of reactive oxygen species in endothelial cells, which may
contribute to the senescence and apoptotic death of endo-
thelial cells. It is now clear that ADMA affects superoxide
anion production by uncoupling of eNOS and other eNOS-
independent pathways.2 In addition, superoxide anion
production can attack the eNOS directly and induceThe Journal of Thoracic and Cadissociation of eNOS dimer into monomer.16 One study
has suggested that the decrease in nitric oxide production
may be related to a reduction of eNOS expression by eleva-
tion of ADMA level in cultured endothelial cells.17
On the basis of these findings, the role of ADMA in the ni-
tric oxide-related endothelial function of the human LITA
vessels used as coronary artery bypass grafts is an important
issue in the treatment of coronary artery disease. ADMA has
been shown to be independently associated with maximum
vasorelaxation in response to acetylcholine in saphenous
veins,18 but whether ADMA affects the endothelium-
dependent relaxation in human arteries is still unknown. In
this study, we found that the acetylcholine-induced, endothe-
lium-dependent relaxation was significantly reduced by in-
cubation of the human LITA with ADMA. This finding
clearly demonstrates that ADMA plays a role in reducing ni-
tric oxide–mediated relaxation in human arteries.
As a novel small–molecular weight compound, AVE3085
increases endothelial nitric oxide production by the simulta-
neous upregulation of eNOS expression and reversal of
eNOS uncoupling.7 Previous studies have indicated that
long-term treatment with AVE3085 significantly increases
eNOS messenger RNA and protein levels in the cardiac
tissues of male Sprague-Dawley rats and male Dahl salt-
sensitive rats.8,9 Further, we have recently demonstrated
that use of AVE3085 protects porcine coronary endo-
thelium from ischemia–reperfusion injury and restores
impaired endothelial function in a hypertensive model by
significantly increasing the eNOS expressions of
endothelial cells.10,11 In addition, AVE3085 has been
shown to ameliorate endothelial dysfunction in db/db mice
through increased nitric oxide bioavailability, which
reduces oxidative stress in the vascular wall.12
Interestingly, we found that the expression of eNOS was
downregulated in human LITA specimens when they wererdiovascular Surgery c Volume 144, Number 3 701
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significantly increased the eNOS protein level. These find-
ings demonstrate that the reduction of the relaxation may
be associated with the downregulation of eNOS, as Jiang
and associates17 suggested that the decrease of the nitric
oxide production may be related to reduction of eNOS
expression by elevation of ADMA level in cultured endo-
thelial cells.
It is well known that superoxide anion impairs vascular
function.3 Recent studies showed that ADMA, an endoge-
nous inhibitor of eNOS, uncoupled eNOS activity to gener-
ate superoxide anion by inhibiting heat shock protein 90
associated with eNOS.19 In accordance with other reports,
we found in this study that ADMA could uncouple eNOS
activity to increase superoxide anion generation in cultured
internal thoracic arteries. In fact, we found that AVE3805
inhibited ADMA-induced superoxide anion generation.
Our findings indicate that AVE3805 may be able to main-
tain the eNOS coupling activity to product nitric oxide in
the human artery, which supports the potential use of
AVE3805 to protect vascular endothelial function in human
disease.
In this study, we tested the hypothesis that the newly de-
veloped eNOS enhancer AVE3085 could play a role in the
restoration of the downregulated eNOS and therefore restore
the acetylcholine-induced, endothelium-dependent relaxa-
tion to a certain extent. The results support this hypothesis,
because incubation of LITA ring segments in AVE3085
(30 mmol/L) significantly improved the acetylcholine-
induced relaxation that was reduced by ADMA alone.
This study also demonstrated that such restoration of the
endothelium-dependent relaxation is associated with
eNOS and superoxide anion changes.Study Limitations
This study is an in vitro experimental investigation at the
tissue (vascular) and molecular levels. Any in vivo protec-
tive effect of AVE3085 on the endothelial function damaged
by ADMA in the LITA and its potential clinical impact on
the long-term patency of the graft remain to be defined.Clinical Implications
Use of eNOS enhancers to restore the reduced nitric ox-
ide–related endothelial function is a new therapeutic strat-
egy that may have clinical implications in a number of
clinical situations associated with endothelial dysfunction,
such as diabetes, hypertension, and ischemia–reperfusion
injury in coronary artery disease, cardiac surgery, or organ
transplants. This study emphasizes that the use of eNOS en-
hancers may improve endothelial function in the human ar-
teries used as grafts in coronary artery bypass grafting and
thus supports the trial of those new drugs as a therapeutic
strategy for the listed pathologic conditions.702 The Journal of Thoracic and Cardiovascular SurgCONCLUSIONS
In conclusion, the results of our study in the human LITA
suggest that increased ADMA levels directly cause endo-
thelial dysfunction by downregulating protein expression
of eNOS and by increasing superoxide production. These
mechanisms of endothelial dysfunction may be partially re-
versed by means of the eNOS enhancer AVE3085. These
findings provide new insights into the protection of the en-
dothelium of the coronary artery bypass grafting conduit to
improve the long-term patency of the grafts.
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